Articles

Single-agent pembrolizumab yielded robust antitumor activity in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma.

Pembrolizumab Demonstrates Robust Activity in Advanced and Recurrent/Metastatic CSCC

Biofrontera announces it is seeking FDA-approval for its new BF-RhodoLED XL lamp to be used in combination with topical aminolevulinic acid hydrochloride gel 10% for the treatment of actinic keratosis.

Biofrontera Seeks FDA-Approval of BF-RhodoLED XL for AK

Cancer staging systems for squamous cell carcinoma have helped improve dermatologists’ ability to accurately stage the cancer, according to one expert.

New Treatments Aim to  Increase Survival Rate 

Almirall announces the launch of tirbanibulin (Klisyri), a novel microtubule inhibitor for the topical treatment of actinic keratosis on the face or scalp. 

Topical Actinic Keratosis Treatment Launched in US

Topical microtubule inhibitor, tirbanibulin (Klisyri, Almirall), demonstrates positive results for treating actinic keratosis (AK) of the face and scalp, according recently published data from two phase 3 studies.

Tirbanibulin Safe, Effective for AK on Face, Scalp

The FDA has approved cemiplimab-rwlc as the first immunotherapy for use in patients with advanced basal cell carcinoma that has previously been treated with a hedgehog pathway inhibitor (HHI) or for whom a HHI is not appropriate.

FDA Approves Cemiplimab for Advanced Basal Cell Carcinoma

A recent study found states' Medicare per-beneficiary spending between actinic keratosis and skin cancer differs widely.

Medicare Spending on Skin Cancer, AK Varies Widely

While Mohs micrographic surgery is well established as a safe and effective therapeutic modality in adult patients, it is not as commonly used in pediatric populations. There are unique challenges to performing Mohs surgery on pediatric patients, especially with patient cooperation. Multidisciplinary planning may be needed.

Mohs micrographic presents challenges in kids 

Investigators of a recent study found a 40-gene expression profile (40-GEP) test helps improve identification of high risk for metastatic disease in patients with cutaneous squamous cell carcinoma (cSCC).

Gene expression profile test predicts metastatic risk

Superficial radiation offers a newer, FDA-approved office-based option that is safe. Steven A. Davis, M.D., shares his experience using surface radiotherapy to treat his patients with non-melanoma skin cancer.

Skin Cancer (Nonmelanoma)